Targeted proteomics improves cardiovascular risk prediction in secondary prevention.
Nick S NurmohamedJoão P Belo PereiraRenate M HoogeveenJeffrey KroonJordan M KraaijenhofFarahnaz WaissiNathalie TimmermanMichiel J BomImo E HoeferPaul KnaapenAlberico Luigi CatapanoWolfgang KoenigDominique P V de KleijnFrank L J VisserenEvgeni LevinErik S G StroesPublished in: European heart journal (2022)
A proteome-based risk model is superior to a clinical risk model in predicting recurrent ASCVD events. Neutrophil-related pathways were found in low CRP patients, implying the presence of a residual inflammatory risk beyond traditional NLRP3 pathways. The observed net reclassification improvement illustrates the potential of proteomics when incorporated in a tailored therapeutic approach in secondary prevention patients.